Microneedling device for Dyschromia

Phase-Based Progress Estimates
Center for Dermatology and Laser Surgery, Sacramento, CA
Dyschromia+2 More
Microneedling device - Device
All Sexes
What conditions do you have?

Study Summary

The intended use of the radiofrequency and microneedling devices used in this study is to assess the efficacy and safety of paired treatment for the treatment of facial aging.

Eligible Conditions

  • Dyschromia
  • Wrinkles
  • Solar Elastosis

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

4 Primary · 0 Secondary · Reporting Duration: 90 day follow up

30 day follow up
% of Photos Identified Correctly of 30 Day Follow Up vs. Baseline
Percent of Photos Identified Correctly of 30 Day Follow Up vs. Baseline
90 day follow up
% of Photos Identified Correctly of 90 Day Follow Up vs. Baseline
Percent of Photos Identified Correctly of 90 Day Follow Up vs. Baseline

Trial Safety

Safety Progress

1 of 3

Trial Design

1 Treatment Group

1 of 1
Experimental Treatment

35 Total Participants · 1 Treatment Group

Primary Treatment: Microneedling device · No Placebo Group · N/A

TreatmentExperimental Group · 2 Interventions: RF device, Microneedling device · Intervention Types: Device, Device

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 90 day follow up
Closest Location: Center for Dermatology and Laser Surgery · Sacramento, CA
Photo of Sacramento 1Photo of Sacramento 2Photo of Sacramento 3
2008First Recorded Clinical Trial
1 TrialsResearching Dyschromia
16 CompletedClinical Trials

Who is running the clinical trial?

Cynosure, Inc.Lead Sponsor
46 Previous Clinical Trials
1,138 Total Patients Enrolled
Jennifer CiviokStudy DirectorDirector of Clinical Development
16 Previous Clinical Trials
502 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 5 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You are a healthy male or female between the age of 40 - 65 years old.
You understand and accept the obligation not to receive any other treatments on the treatment area.
You understand and accept the obligation to be present for all visits.
You are willing to comply with all requirements of the study and sign the informed consent document.

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.